Cargando…

Slowed Metabolic Decline After 1 Year of Oral Insulin Treatment Among Individuals at High Risk for Type 1 Diabetes in the Diabetes Prevention Trial–Type 1 (DPT-1) and TrialNet Oral Insulin Prevention Trials

We assessed whether oral insulin slowed metabolic decline after 1 year of treatment in individuals at high risk for type 1 diabetes. Two oral insulin trials that did not show efficacy overall and had type 1 diabetes as the primary end point were analyzed: the Diabetes Prevention Trial–Type 1 (DPT-1)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sosenko, Jay M., Skyler, Jay S., Herold, Kevan C., Schatz, Desmond A., Haller, Michael J., Pugliese, Alberto, Cleves, Mario, Geyer, Susan, Rafkin, Lisa E., Matheson, Della, Palmer, Jerry P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2020
Materias:	Pharmacology and Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7372067/ https://www.ncbi.nlm.nih.gov/pubmed/32439823 http://dx.doi.org/10.2337/db20-0166

Ejemplares similares

Glucose Excursions Between States of Glycemia With Progression to Type 1 Diabetes in the Diabetes Prevention Trial–Type 1 (DPT-1)
por: Sosenko, Jay M., et al.
Publicado: (2010)

Validation of the Diabetes Prevention Trial–Type 1 Risk Score in the TrialNet Natural History Study
por: Sosenko, Jay M., et al.
Publicado: (2011)

Acceleration of the Loss of the First-Phase Insulin Response During the Progression to Type 1 Diabetes in Diabetes Prevention Trial–Type 1 Participants
por: Sosenko, Jay M., et al.
Publicado: (2013)

Erratum. Validation of the Diabetes Prevention Trial–Type 1 Risk Score in the TrialNet Natural History Study. Diabetes Care 2011;34:1785–1787
por: Sosenko, Jay M., et al.
Publicado: (2018)

The Metabolic Progression to Type 1 Diabetes as Indicated by Serial Oral Glucose Tolerance Testing in the Diabetes Prevention Trial–Type 1
por: Sosenko, Jay M., et al.
Publicado: (2012)

Glucose and C-Peptide Changes in the Perionset Period of Type 1 Diabetes in the Diabetes Prevention Trial–Type 1
por: Sosenko, Jay M., et al.
Publicado: (2008)

Long-Term Outcome of Individuals Treated With Oral Insulin: Diabetes Prevention Trial–Type 1 (DPT-1) oral insulin trial
por: Vehik, Kendra, et al.
Publicado: (2011)

Trends of Earlier and Later Responses of C-peptide to Oral Glucose Challenges With Progression to Type 1 Diabetes in Diabetes Prevention Trial–Type 1 Participants
por: Sosenko, Jay M., et al.
Publicado: (2010)

A Longitudinal Study of GAD65 and ICA512 Autoantibodies During the Progression to Type 1 Diabetes in Diabetes Prevention Trial–Type 1 (DPT-1) Participants
por: Sosenko, Jay M., et al.
Publicado: (2011)

Use of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for Improving the Accuracy of the Risk Classification of Type 1 Diabetes
por: Sosenko, Jay M., et al.
Publicado: (2014)

Incident Dysglycemia and Progression to Type 1 Diabetes Among Participants in the Diabetes Prevention Trial–Type 1
por: Sosenko, Jay M., et al.
Publicado: (2009)

The Application of the Diabetes Prevention Trial–Type 1 Risk Score for Identifying a Preclinical State of Type 1 Diabetes
por: Sosenko, Jay M., et al.
Publicado: (2012)

Development of Autoantibodies in the TrialNet Natural History Study
por: Vehik, Kendra, et al.
Publicado: (2011)

Understanding and preventing type 1 diabetes through the unique working model of TrialNet
por: Battaglia, Manuela, et al.
Publicado: (2017)

Erratum. Who Is Enrolling? The Path to Monitoring in Type 1 Diabetes TrialNet’s Pathway to Prevention. Diabetes Care 2019;42:2228–2236
por: Sims, Emily K., et al.
Publicado: (2020)

Pancreatic Islet Autoantibodies as Predictors of Type 1 Diabetes in the Diabetes Prevention Trial–Type 1
por: Orban, Tihamer, et al.
Publicado: (2009)

Fall in C-Peptide During First 2 Years From Diagnosis: Evidence of at Least Two Distinct Phases From Composite Type 1 Diabetes TrialNet Data
por: Greenbaum, Carla J., et al.
Publicado: (2012)

George S. Eisenbarth: Insulin and Type 1 Diabetes
por: Pugliese, Alberto, et al.
Publicado: (2013)

Impact of Diabetes Susceptibility Loci on Progression From Pre-Diabetes to Diabetes in At-Risk Individuals of the Diabetes Prevention Trial–Type 1 (DPT-1)
por: Butty, Vincent, et al.
Publicado: (2008)

Diabetic Subjects Diagnosed Through the Diabetes Prevention Trial–Type 1 (DPT-1) Are Often Asymptomatic With Normal A1C at Diabetes Onset
por: Triolo, Taylor M., et al.
Publicado: (2009)

Dysglycemia and Index60 as Prediagnostic End Points for Type 1 Diabetes Prevention Trials
por: Nathan, Brandon M., et al.
Publicado: (2017)

Stopping Type 1 Diabetes: Attempts to Prevent or Cure Type 1 Diabetes in Man
por: Skyler, Jay S., et al.
Publicado: (2011)

The Prediction of Type 1 Diabetes by Multiple Autoantibody Levels and Their Incorporation Into an Autoantibody Risk Score in Relatives of Type 1 Diabetic Patients
por: Sosenko, Jay M., et al.
Publicado: (2013)

A New Approach for Diagnosing Type 1 Diabetes in Autoantibody-Positive Individuals Based on Prediction and Natural History
por: Sosenko, Jay M., et al.
Publicado: (2015)

Progression to Diabetes in Relatives of Type 1 Diabetic Patients: Mechanisms and Mode of Onset
por: Ferrannini, Ele, et al.
Publicado: (2010)

Oral insulin therapy for primary prevention of type 1 diabetes in infants with high genetic risk: the GPPAD-POInT (global platform for the prevention of autoimmune diabetes primary oral insulin trial) study protocol
por: Ziegler, Anette-Gabriele, et al.
Publicado: (2019)

Oral insulin immunotherapy in children at risk for type 1 diabetes in a randomised controlled trial
por: Assfalg, Robin, et al.
Publicado: (2021)

Islet Autoantibody Seroconversion in the DPT-1 Study: Justification for repeat screening throughout childhood
por: Vehik, Kendra, et al.
Publicado: (2011)

Prognostic Performance of Metabolic Indexes in Predicting Onset of Type 1 Diabetes
por: Xu, Ping, et al.
Publicado: (2010)

An Insulin‐Inspired Supramolecular Hydrogel for Prevention of Type 1 Diabetes
por: Liu, Mohan, et al.
Publicado: (2021)

Acute Metabolic Effects of Exenatide in Patients With Type 1 Diabetes With and Without Residual Insulin to Oral and Intravenous Glucose Challenges
por: Ghazi, Tara, et al.
Publicado: (2014)

Prognostic Accuracy of Immunologic and Metabolic Markers for Type 1 Diabetes in a High-Risk Population: Receiver operating characteristic analysis
por: Xu, Ping, et al.
Publicado: (2012)

The Deterrence of Rapid Metabolic Decline Within 3 Months After Teplizumab Treatment in Individuals at High Risk for Type 1 Diabetes
por: Sims, Emily K., et al.
Publicado: (2021)

Type 1 Diabetes at a Crossroads!
por: Cefalu, William T., et al.
Publicado: (2015)

The Compelling Case for Anti-CD3 in Type 1 Diabetes
por: Skyler, Jay S.
Publicado: (2013)

Risk Factors and Primary Prevention Trials for Type 1 Diabetes
por: Wu, Yan-Ling, et al.
Publicado: (2013)

Barriers to Screening: An Analysis of Factors Impacting Screening for Type 1 Diabetes Prevention Trials
por: Kinney, Mara, et al.
Publicado: (2023)

The effect of age on longitudinal measures of beta cell function and insulin sensitivity during the progression of early stage type 1 diabetes
por: Ferrannini, Ele, et al.
Publicado: (2022)

Glucagon Receptor Knockout Prevents Insulin-Deficient Type 1 Diabetes in Mice
por: Lee, Young, et al.
Publicado: (2011)

Association of HLA-DQ Heterodimer Residues −18β and β57 With Progression From Islet Autoimmunity to Diabetes in the Diabetes Prevention Trial–Type 1
por: Zhao, Lue Ping, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9079asnqqmv2mfo0gq45g5fl20